1.Tsurusaki M, Murakami T: Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015, 4(3):165–175.
2.Zhang Y, Huang L, Shi H, Chen H, Tao J, Shen R, Wang T: Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance. Cancer Sci 2018, 109(1):94–102.
3.Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, Xue TC, Zhang QB, Wang YH, Zhang L et al: Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma Is Associated with Increased Autocrine of IGF1. PLoS One 2014, 9(3).
4.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015, 65(2):87–108.
5.Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y et al: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013, 31(28):3501–3508.
6.Sievers E, Trautmann M, Kindler D, Huss S, Gruenewald I, Dirksen U, Renner M, Mechtersheimer G, Pedeutour F, Aman P et al: SRC inhibition represents a potential therapeutic strategy in liposarcoma. Int J Cancer 2015, 137(11):2578–2588.
7.Roseweir AK, Qayyum T, Lim Z, Hammond R, MacDonald AI, Fraser S, Oades GM, Aitchison M, Jones RJ, Edwards J: Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer 2016, 16:229.
8.Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L: CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases. Oncogene 2015, 34(44):5593–5598.
9.Zhao R, Wu Y, Wang T, Zhang Y, Kong D, Zhang L, Li X, Wang G, Jin Y, Jin X et al: Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients. Oncol Lett 2015, 10(5):3026–3034.
10.Zhao S, Li H, Wang Q, Su C, Wang G, Song H, Zhao L, Luan Z, Su R: The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated alpha2M. BMC Cancer 2015, 15:389.
11.Van Kolen K, Gilany K, Moens L, Esmans EL, Slegers H: P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1. Cell Signal 2006, 18(8):1169–1181.
12.Sekharam M, Nasir A, Kaiser HE, Coppola D: Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003, 23(2B):1517–1524.
13.Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, Xue TC, Zhang QB, Wang YH, Zhang L et al: Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One 2014, 9(3):e89686.
14.Anguita E, Villalobo A: Ca(2+) signaling and Src-kinases-controlled cellular functions. Arch Biochem Biophys 2018.
15.Liu Y, Zhang X, Yang B, Zhuang H, Guo H, Wei W, Li Y, Chen R, Zhang N: Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC. Cancer Res 2018, 78(9):2219–2232.
16.Xu L, Tong X, Zhang S, Yin F, Li X, Wei H, Li C, Guo Y, Zhao J: ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma. Tumour Biol 2016, 37(10):13669–13677.
17.Lang L, Shay C, Xiong Y, Thakkar P, Chemmalakuzhy R, Wang X, Teng Y: Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. J Hematol Oncol 2018, 11(1):85.
18.Tanaka S, Hosokawa M, Yonezawa T, Hayashi W, Ueda K, Iwakawa S: Induction of epithelial-mesenchymal transition and down-regulation of miR–200c and miR–141 in oxaliplatin-resistant colorectal cancer cells. Biol Pharm Bull 2015, 38(3):435–440.
19.Yamaguchi H, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R: Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. Cancer Sci 2014, 105(5):528–536.
20.Namba Y, Sogawa C, Okusha Y, Kawai H, Itagaki M, Ono K, Murakami J, Aoyama E, Ohyama K, Asaumi JI et al: Depletion of Lipid Efflux Pump ABCG1 Triggers the Intracellular Accumulation of Extracellular Vesicles and Reduces Aggregation and Tumorigenesis of Metastatic Cancer Cells. Front Oncol 2018, 8:376.
21.Li K, Lai H: TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters. Biomed Pharmacother 2017, 96:371–377.